REMODEL-1 and REMODEL-2: remibrutinib lowered relapse rates versus teriflunomide
The Lancet published REMODEL-1 and REMODEL-2 results on 23 October 2026. Adults with relapsing multiple sclerosis received remibrutinib 100 mg twice daily or teriflunomide 14 mg daily. The PubMed article abstract reports annualised relapse rates of 0.073 versus 0.112 in REMODEL-1 (rate ratio 0.648, 95% CI 0.453–0.927) and 0.080 versus 0.116 in REMODEL-2 (0.688, 0.487–0.972). The abstract reports common adverse events and fewer adverse-event-related treatment discontinuations with remibrutinib (3.1% versus 5.8%) and says there were no liver safety concerns. In its 23 October announcement, Novartis reports rises in the liver enzyme ALT above three times the normal limit in 2.0% of people on remibrutinib versus 7.4% on teriflunomide across both trials, and no Hy's Law cases with remibrutinib (a pattern that can signal serious drug-related liver injury); a 29.2% lower risk of disability worsening confirmed as lasting at least 6 months; and 65% and 70% lower T2 lesion activity on MRI in the two trials. These figures are the company's; the full paper and its safety appendix were not reviewed here. These RMS trials are distinct from the separate REMASTER trial in secondary progressive MS.
Source: The Lancet — PubMed indexed primary-article abstract ↗Source: REMODEL-1 official trial record ↗ Source: REMODEL-2 official trial record ↗ Source: Novartis announcement, 23 October 2026 ↗ Source: EMA — Aubagio (teriflunomide) product information ↗